Identification of candidate responders for anti-PD-L1/PD-1 immunotherapy, Rova-T therapy, or EZH2 inhibitory therapy in small-cell lung cancer

A useful candidate for small-cell lung cancer (SCLC) therapy is immune checkpoint blockade therapy targeting programmed death-1 (PD-1) and its ligand, PD-L1. Furthermore, rovalpituzumab tesirine (Rova-T), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate, and enhancer of zeste homologue...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Mol Clin Oncol
Main Authors: Saito, Motonobu, Saito, Katsuharu, Shiraishi, Kouya, Maeda, Daichi, Suzuki, Hiroyuki, Minamiya, Yoshihiro, Kono, Koji, Kohno, Takashi, Goto, Akiteru
Format: Artigo
Jezik:Inglês
Izdano: D.A. Spandidos 2018
Teme:
Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5776411/
https://ncbi.nlm.nih.gov/pubmed/29435295
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2017.1536
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki